Gilead Sciences has agreed to acquire an oral IL-23R inhibitor program, led by HCXT-2001, from privately held PepStar ...
Rising trial amendments drive costly change orders, but AI tools help sponsors spot hidden costs and negotiate better final ...
Zymeworks entered into a global licensing and collaboration agreement with Roche for ZW209, a trispecific T-cell engager ...
Racura is pursuing one of cancer’s most elusive targets, pairing a distinctive MYC-inhibition approach with a data-first path ...
Earlier this week, Eli Lilly announced it broke ground on a large site in Houston, Texas. The location will be one of ten US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results